Coagulation Disorders in Patients With Cirrhosis
Publication Date: September 23, 2021
Key Points
Key Points
- Significant alterations in laboratory parameters — such as platelet count (PLT) and prothrombin time/international normalized ratio (PT/INR) — routinely accompany cirrhosis.
- However, the risks of both bleeding and thrombosis are not accurately quantitated by standard testing in this population.
- The best strategies to identify patients at risk for bleeding or thrombosis, to provide appropriate prophylaxis in patients at risk for clinically significant bleeding, to screen for and treat portal vein thrombosis, and to prevent clinically significant thromboembolic events are currently unknown.
Diagnosis
...agnosis
...esting Stra...
...stic Testing (VET)In patients with stable...
...NRIn patients with stable cirrhosis (with known ba...
...ortal Vein Thrombosis (PVT) Scre...
...ients with cirrhosis, the AGA suggests aga...
Treatment
...atment
Preprocedure Prophylaxi...
...sh Frozen Plasma (FFP)In patients with sta...
...etin receptor agonist (TPO-Ras)In patients with th...
...ous Thromboembolism (VTE) Prophylaxis With Anticoa...
...spitalized patients with cirrhosis and who...
...ubacute Non-tumoral Portal Vein Thrombos...
...ts with cirrhosis and acute or subacute...
...al Fibrillation...
...s with cirrhosis and atrial fibrillation with an...
...rocedure Risk StratificationHaving trouble...